Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 2 | 2011 | 191 | 0.680 |
Why?
|
| Vaccination | 2 | 2015 | 1123 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 1209 | 0.650 |
Why?
|
| Nucleic Acids | 1 | 2017 | 43 | 0.590 |
Why?
|
| Kidney Transplantation | 2 | 2013 | 755 | 0.570 |
Why?
|
| HIV | 1 | 2017 | 229 | 0.540 |
Why?
|
| Influenza, Human | 2 | 2015 | 925 | 0.530 |
Why?
|
| Infection Control | 2 | 2014 | 270 | 0.510 |
Why?
|
| Hematologic Neoplasms | 3 | 2014 | 1870 | 0.480 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2014 | 427 | 0.480 |
Why?
|
| Respiratory Tract Infections | 3 | 2014 | 437 | 0.480 |
Why?
|
| Drug Resistance, Microbial | 1 | 2014 | 218 | 0.480 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 204 | 0.470 |
Why?
|
| Liver Transplantation | 2 | 2012 | 1112 | 0.440 |
Why?
|
| Klebsiella Infections | 1 | 2012 | 64 | 0.410 |
Why?
|
| Peritonitis | 1 | 2012 | 89 | 0.410 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2011 | 44 | 0.410 |
Why?
|
| Mycobacterium Infections | 1 | 2011 | 49 | 0.410 |
Why?
|
| Liver Diseases, Parasitic | 1 | 2011 | 4 | 0.400 |
Why?
|
| Klebsiella pneumoniae | 1 | 2012 | 98 | 0.400 |
Why?
|
| Schistosoma | 1 | 2011 | 11 | 0.400 |
Why?
|
| Community-Acquired Infections | 1 | 2014 | 285 | 0.400 |
Why?
|
| Environmental Exposure | 1 | 2014 | 288 | 0.400 |
Why?
|
| Herpesvirus 8, Human | 1 | 2011 | 102 | 0.390 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 50 | 0.390 |
Why?
|
| Hematoma | 1 | 2012 | 160 | 0.380 |
Why?
|
| Schistosomiasis | 1 | 2011 | 63 | 0.380 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 482 | 0.370 |
Why?
|
| Herpesviridae Infections | 1 | 2011 | 175 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 573 | 0.370 |
Why?
|
| Mycoses | 1 | 2014 | 386 | 0.370 |
Why?
|
| Drug Resistance | 1 | 2011 | 587 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 1303 | 0.350 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 462 | 0.350 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 635 | 0.350 |
Why?
|
| Vaccines | 1 | 2014 | 389 | 0.350 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2011 | 211 | 0.340 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 748 | 0.330 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 321 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2014 | 6550 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 242 | 0.310 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 446 | 0.300 |
Why?
|
| HIV Infections | 2 | 2017 | 2134 | 0.300 |
Why?
|
| Heart Transplantation | 1 | 2012 | 908 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 918 | 0.250 |
Why?
|
| Lung Diseases | 1 | 2010 | 717 | 0.250 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3869 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 2403 | 0.240 |
Why?
|
| Clinical Competence | 1 | 2011 | 1270 | 0.230 |
Why?
|
| Neoplasms | 4 | 2017 | 15193 | 0.220 |
Why?
|
| Physicians | 1 | 2011 | 882 | 0.220 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 22 | 0.200 |
Why?
|
| Florida | 2 | 2011 | 113 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2013 | 5542 | 0.190 |
Why?
|
| Antiviral Agents | 4 | 2014 | 1230 | 0.170 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2018 | 12 | 0.160 |
Why?
|
| Ehrlichiosis | 1 | 2018 | 20 | 0.160 |
Why?
|
| Cross Infection | 2 | 2014 | 544 | 0.160 |
Why?
|
| Ribavirin | 3 | 2014 | 178 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 2992 | 0.150 |
Why?
|
| Receptors, Antigen | 1 | 2017 | 76 | 0.150 |
Why?
|
| Neutropenia | 1 | 2021 | 968 | 0.150 |
Why?
|
| Humans | 22 | 2021 | 261506 | 0.150 |
Why?
|
| Risk Factors | 6 | 2014 | 17523 | 0.150 |
Why?
|
| Middle Aged | 11 | 2018 | 86204 | 0.130 |
Why?
|
| Herbaspirillum | 1 | 2014 | 6 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 362 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2018 | 583 | 0.120 |
Why?
|
| Male | 13 | 2015 | 123000 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 406 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2015 | 430 | 0.120 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2013 | 11 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2018 | 834 | 0.120 |
Why?
|
| beta-Lactams | 1 | 2013 | 53 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2014 | 37905 | 0.110 |
Why?
|
| Ganciclovir | 1 | 2013 | 174 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 158 | 0.110 |
Why?
|
| Aged | 9 | 2015 | 70117 | 0.110 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 698 | 0.110 |
Why?
|
| Female | 13 | 2018 | 141928 | 0.110 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2013 | 72 | 0.110 |
Why?
|
| Organ Preservation Solutions | 1 | 2012 | 20 | 0.110 |
Why?
|
| Young Adult | 5 | 2015 | 21445 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 317 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 620 | 0.100 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2011 | 13 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 228 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2014 | 238 | 0.100 |
Why?
|
| Hospitalization | 2 | 2011 | 2083 | 0.100 |
Why?
|
| Adolescent | 6 | 2015 | 31252 | 0.100 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 231 | 0.100 |
Why?
|
| Housekeeping, Hospital | 1 | 2011 | 2 | 0.100 |
Why?
|
| Praziquantel | 1 | 2011 | 15 | 0.100 |
Why?
|
| Castleman Disease | 1 | 2011 | 69 | 0.100 |
Why?
|
| Anthelmintics | 1 | 2011 | 69 | 0.100 |
Why?
|
| Debridement | 1 | 2011 | 123 | 0.100 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2012 | 148 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1664 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 350 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2011 | 118 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 202 | 0.090 |
Why?
|
| beta-Lactamases | 1 | 2012 | 179 | 0.090 |
Why?
|
| Hypertension, Portal | 1 | 2011 | 124 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 450 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 1 | 2011 | 187 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 994 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 575 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 459 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2011 | 289 | 0.080 |
Why?
|
| Logistic Models | 1 | 2015 | 3441 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 462 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2012 | 769 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.080 |
Why?
|
| Self Report | 1 | 2011 | 756 | 0.080 |
Why?
|
| Radiography | 1 | 2011 | 1904 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 2315 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2012 | 1029 | 0.070 |
Why?
|
| Adult | 6 | 2015 | 77950 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 181 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 941 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2014 | 9244 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 29902 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 3719 | 0.060 |
Why?
|
| Liver | 1 | 2011 | 2961 | 0.050 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 577 | 0.040 |
Why?
|
| Biological Products | 1 | 2021 | 274 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2018 | 335 | 0.040 |
Why?
|
| Betaproteobacteria | 1 | 2014 | 6 | 0.030 |
Why?
|
| Burkholderia cepacia | 1 | 2014 | 7 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 128 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 103 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 55 | 0.030 |
Why?
|
| Palivizumab | 1 | 2014 | 64 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 20 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7551 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 72 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 61 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2014 | 16273 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2014 | 285 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 171 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2014 | 490 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2014 | 558 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 1375 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 59536 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 544 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 2238 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 2638 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2483 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 5673 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3251 | 0.010 |
Why?
|
| Child | 2 | 2014 | 29154 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2014 | 32848 | 0.010 |
Why?
|
| Texas | 1 | 2014 | 6311 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 14889 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 6915 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 13658 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 21713 | 0.010 |
Why?
|